H-LEU-SER-LYS-LEU-NH2
H-LEU-SER-LYS-LEU-NH2 Basic information
- Product Name:
- H-LEU-SER-LYS-LEU-NH2
- Synonyms:
-
- INHIBITOR OF THROMBOSPONDIN (TSP-1)
- LEU-SER-LYS-LEU-NH2
- H-LEU-SER-LYS-LEU-NH2
- LSKL
- LSKL-NH2
- Leu-Ser-Lys-Leu peptide
- LSKL, BR
- H-Leu-Ser-Lys-Leu-NH?
- CAS:
- 283609-79-0
- MF:
- C21H42N6O5
- MW:
- 458.6
- Product Categories:
-
- peptide
- Other Peptides
- Peptides and Proteins
- Peptides for Cell Biology
- Mol File:
- Mol File
H-LEU-SER-LYS-LEU-NH2 Chemical Properties
- Boiling point:
- 817.8±65.0 °C(Predicted)
- Density
- 1.143±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- solubility
- DMSO : ≥ 100 mg/mL (218.05 mM)
- pka
- 13.40±0.46(Predicted)
- form
- Solid
- color
- White to off-white
- Sequence
- H-Leu-Ser-Lys-Leu-NH2
MSDS
- Language:English Provider:SigmaAldrich
H-LEU-SER-LYS-LEU-NH2 Usage And Synthesis
Uses
L-Leucyl-L-seryl-L-lysyl-L-leucinamide can be useful in the study of relative contributions of core protein and solvation shell in terahertz dielectric properties of protein solutions.
in vivo
LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling[1].
LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy[3].
| Animal Model: | 103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)[1] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus. |
H-LEU-SER-LYS-LEU-NH2Supplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 025-846993838003-8003 18013301590
- njduly@126.com
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
H-LEU-SER-LYS-LEU-NH2(283609-79-0)Related Product Information
- H-GLY-GLY-SER-LEU-TYR-SER-PHE-GLY-LEU-NH2
- ALLATOSTATIN IV
- RGDV
- AUTOCAMTIDE-2-RELATED INHIBITORY PEPTIDE
- Z-Ile-Glu-Pro-Phe-OMe
- ATRIAL NATRIURETIC FACTOR (1-28) (RAT)
- H-GLY-ASP-GLY-ARG-LEU-TYR-ALA-PHE-GLY-LEU-NH2
- ALLATOSTATIN I
- RIP
- H-LEU-SER-ALA-LEU-OH
- H-LEU-SER-LYS-LEU-OH
- H-VAL-PRO-PRO-OH
- PEP2M
- Histatin 5
- Aprotinin
- (D-ALA1)-PEPTIDE T AMIDE
- CYCLO(-ARG-GLY-ASP-D-TYR-LYS)